PLX (Protalix BioTherapeutics) Additional Paid-In Capital: $434.23 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
60 GF Score
Price $2.68
GF Value $2.20
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Additional Paid-In Capital?

Protalix BioTherapeutics PLX +0.37% 60 Additional Paid-In Capital is $434.23 Mil as of Jun. 2026. GuruFocus rates PLX with a GF Score™ of 60/100 and a GF Value™ of $2.20 (Modestly Overvalued). The stock has 5 warning signs investors should review.


Protalix BioTherapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($433.15 Mil) to Mar. 2026 ($433.83 Mil) and increased from Mar. 2026 ($433.83 Mil) to Jun. 2026 ($434.23 Mil).

Protalix BioTherapeutics's annual additional paid-in capital increased from Dec. 2023 ($415.05 Mil) to Dec. 2024 ($421.53 Mil) and increased from Dec. 2024 ($421.53 Mil) to Dec. 2025 ($433.15 Mil).

Protalix BioTherapeutics Additional Paid-In Capital Related Terms

Protalix BioTherapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Additional Paid-In Capital Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 368.85 379.17 415.05 421.53 433.15

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 431.67 432.32 433.15 433.83 434.23
PLX
60GF Score
Protalix BioTherapeutics Inc PLX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $434.23 Mil mean?
Protalix BioTherapeutics (PLX) has a Additional Paid-In Capital of $434.23 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Additional Paid-In Capital too high?
Protalix BioTherapeutics' current Additional Paid-In Capital is $434.23 Mil. Overall, Protalix BioTherapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Additional Paid-In Capital compare to CUE and ORMP?
Protalix BioTherapeutics' Additional Paid-In Capital of $434.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Additional Paid-In Capital is $434.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.20, compared to a current price of $2.68 — trading 21.8% above its estimated fair value. The current Additional Paid-In Capital is $434.23 Mil. Protalix BioTherapeutics' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Additional Paid-In Capital is $434.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.68 is trading 21.8% above its estimated GF Value™ of $2.20. GuruFocus considers Protalix BioTherapeutics to be Modestly Overvalued.

Key valuation signals for PLX:

  • Additional Paid-In Capital: $434.23 Mil
  • GF Value™: $2.20 vs. price of $2.68 (21.8% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
60GF Score

Get the complete analysis for PLX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.68
Price
$2.20
GF Value